Jagiełło-Gruszfeld, A.I.; Rosinska, M.; Meluch, M.; Pogoda, K.; Niwinska, A.; Sienkiewicz, R.; Grous, A.; Winter, P.; Nowecki, Z.I.
Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers 2022, 14, 1218.
https://doi.org/10.3390/cancers14051218
AMA Style
Jagiełło-Gruszfeld AI, Rosinska M, Meluch M, Pogoda K, Niwinska A, Sienkiewicz R, Grous A, Winter P, Nowecki ZI.
Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers. 2022; 14(5):1218.
https://doi.org/10.3390/cancers14051218
Chicago/Turabian Style
Jagiełło-Gruszfeld, Agnieszka Irena, Magdalena Rosinska, Małgorzata Meluch, Katarzyna Pogoda, Anna Niwinska, Renata Sienkiewicz, Aleksander Grous, Paweł Winter, and Zbigniew I. Nowecki.
2022. "Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland" Cancers 14, no. 5: 1218.
https://doi.org/10.3390/cancers14051218
APA Style
Jagiełło-Gruszfeld, A. I., Rosinska, M., Meluch, M., Pogoda, K., Niwinska, A., Sienkiewicz, R., Grous, A., Winter, P., & Nowecki, Z. I.
(2022). Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers, 14(5), 1218.
https://doi.org/10.3390/cancers14051218
